Leukocyte Adhesion Deficiency Type I

First FDA-Approved Gene Therapy for Severe Leukocyte Adhesion Deficiency

KRESLADI (marnetegragene autotemcel) — one-time gene therapy for children with severe leukocyte adhesion deficiency type I when no matched sibling donor is available

FDA accelerated approval on 26 March 2026 for KRESLADI (marnetegragene autotemcel) suspension — an autologous hematopoietic stem cell-based gene therapy for…

This is for families of children with severe LAD-I from confirmed ITGB2 gene changes who do not have an HLA-matched sibling donor and who may be candidates for…